Shareholding disclosure

Catalyst Pharmaceuticals, Inc

Declared position

11.26%

Threshold

Crossed upwards

Timeline

Published

27.06.2023

Transaction

19.06.2023

Voting rights breakdown

Voting rights acquired11.26%

Voting rights sold0%

Below threshold0%

Notice details

CategorySingle shareholder

ExchangeXSWX

Notification ID

TAN6N00072

Beneficial owner

Catalyst Pharmaceuticals, Inc

Declared address

Catalyst Pharmaceuticals, Inc., Coral Gables, Florida

Open shareholder profile Open company profile

Back to the feed

Shareholding disclosure

Catalyst Pharmaceuticals, Inc

Santhera Pharmaceuticals Holding AG27.06.2023TAN6N00072

Disclosure summary

Catalyst Pharmaceuticals, Inc disclosed a holding in Santhera Pharmaceuticals Holding AG on the acquisition side, published by SIX Exchange Regulation on 27.06.2023, at 11.26% of voting rights. Notice category: Single shareholder.

Disclosed position

11.26%

Voting rights acquired

Voting rights acquired11.26%

Voting rights sold0%

Below threshold0%

Never miss a market signal again

Create a free account

Need more? Discover the Pro plan

Pro alertsEmail and Telegram after publication

Unlimited company trackingUnlimited watchlist with the Pro plan

Monday recapYour stocks' essentials at the open

Disclosure detail

Catalyst Pharmaceuticals, Inc disclosed a holding in Santhera Pharmaceuticals Holding AG, published on 27.06.2023.

Publication date27.06.2023

Transaction date19.06.2023

Issuing companySanthera Pharmaceuticals Holding AG

Beneficial ownerCatalyst Pharmaceuticals, Inc

Declared addressCatalyst Pharmaceuticals, Inc., Coral Gables, Florida

CategorySingle shareholder

Voting rights acquired11.26%

Voting rights sold0%

Below threshold0%

ExchangeXSWX

Notification IDTAN6N00072

Source: SIX Exchange Regulation · Publication date: 27.06.2023

These figures aggregate public disclosures. They are not investment advice.

insider24.ch

Never miss a market signal again

Create a free account

Need more? Discover the Pro plan

Pro alertsEmail and Telegram after publication

Unlimited company trackingUnlimited watchlist with the Pro plan

Monday recapYour stocks' essentials at the open